Role of the endocannabinoid system in alcoholic liver disease

Digestive Diseases

Volumn 28, Issue 6, 2010, Pages 751-755

  Siegmund, S V ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

2 Arachidonoyl glycerol; Alcoholic liver disease; Anandamide; Cannabinoid receptors; Endocannabinoids

Indexed keywords

ALCOHOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID;

ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; FIBROGENESIS; KNOCKOUT MOUSE; LIPOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL; WILD TYPE;

ANIMALS; ENDOCANNABINOIDS; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES, ALCOHOLIC;

EID: 79955594263     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324283     Document Type: Article

References (29)

1. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005; 115: 209-218. (Pubitemid 40385459)
2. Siegmund SV, Brenner DA: Molecular pathogenesis of alcohol-induced hepatic fibrosis. Alcohol Clin Exp Res 2005; 29: 102S- 109S. (Pubitemid 43194335)
3. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65. (Pubitemid 23305569)
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
5. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-784. (Pubitemid 39242829)
6. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83-87. (Pubitemid 26374593)
7. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819-10824.
8. Pacher P, Ungvari Z: Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases. Am J Physiol Heart Circ Physiol 2008; 294:H1133-H1134. (Pubitemid 351468707)
9. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, Nakayama M, Kaikita K, Obata T, Takeya M, Ogawa H: Activated endocannabinoid system in coronary artery disease and anti-inflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28-36.
10. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-1209. (Pubitemid 38544105)
11. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yuce B, Sibaev A, Massa F, Buckley NE, Lutz B, Goke B, Brand S, Patel KD, Sharkey KA: Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med 2008; 86: 925-936.
12. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA: Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 2009; 15: 1678-1685.
13. Storr M, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkuhn T, Goke B, Lohse P, Brand S: The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. PLoS One 2010; 5:e9453.
14. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P, Horiguchi N, Harvey-White J, Marsicano G, Lutz B, Gao B, Kunos G: Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008; 7: 227-235. (Pubitemid 351285525)
15. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305. (Pubitemid 40629049)
16. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G: Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169.
17. Siegmund SV, Schwabe RF: Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008; 294:G357-G362. (Pubitemid 351253327)
18. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S: Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-755. (Pubitemid 40585376)
19. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, Serriere-Lanneau V, Ledent C, Mallat A, Lotersztajn S: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671-676. (Pubitemid 43865236)
20. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF: Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005; 41: 1085-1095. (Pubitemid 40593916)
21. Siegmund SV, Seki E, Osawa Y, Uchinami H, Cravatt BF, Schwabe RF: Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J Biol Chem 2006; 281: 10431-10438. (Pubitemid 43864582)
22. Siegmund SV, Qian T, de Minicis S, Harvey- White J, Kunos G, Vinod KY, Hungund B, Schwabe RF: The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 2007; 21: 2798-2806. (Pubitemid 47372747)
23. Schwabe RF, Siegmund SV: Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C. Hepatology 2005; 42: 975-976.
24. Biecker E, Sagesser H, Reichen J: Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase-3-deficient mice. Eur J Clin Invest 2004; 34: 283-289. (Pubitemid 38553598)
25. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF: Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007; 132: 1937-1946. (Pubitemid 46677935)
26. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A: Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71. (Pubitemid 40911312)
27. Trebicka J, Racz I, Siegmund SV, Cara E, Granzow M, Klein S, Schierwagen R, Wojtalla A, Hennenberg M, Huss S, Fischer H, Heller J, Zimmer A, Sauerbruch T: Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor deficient mice and decreased in CB1 receptor knockouts. Liver Int 2011 (in press).
28. Louvet A, Teixeira-Clerc F, Deveaux V, Chobert MN, Pavoine C, Mallat A, Lotersztajn S: Beneficial effects of cannabinoid receptor- 2 on alcoholic liver disease. J Hepatol 2010; 52(suppl 1):S307-S308.
29. Patsenker E, Wissniowski T, Millonig G, Mueller S, Stoll M, Ocker M, Seitz HK, Stickel F: Cannabinoid receptor type 1 expression modulates alcohol-induced liver fibrosis: role of acetaldehyde. J Hepatol 2010; 52(suppl 1):S376.